CION Ameerpet
A lymphoma biopsy report can look like a wall of unfamiliar words — CD markers, Ki-67, cell-of-origin. This plain-language guide walks through reading a lymphoma report line by line, so you understand your diagnosis before treatment begins.
A lymphoma biopsy report (also called a pathology or histopathology report) is the document a pathologist writes after examining the tissue removed during your biopsy. It is the single most important piece of information in your diagnosis, because it is what confirms whether you have lymphoma, which exact subtype it is, and the biological features that will guide treatment. Everything that follows — the stage, the plan, the expected outlook — is built on this report.
Reading a lymphoma report can feel overwhelming. It is written for other doctors, so it is dense with abbreviations and marker names. But the structure is consistent, and once you know what each section is for, it becomes far less intimidating. This page explains a lymphoma diagnosis report from top to bottom: the specimen description, the microscopic findings, the immunohistochemistry and flow cytometry panels, the growth-fraction estimate, molecular tests, and — most importantly — the final diagnosis line.
For the wider picture of lymphoma care, see our Lymphoma hub, and for how the diagnosis translates into a plan, our Lymphoma Treatment in Hyderabad page. If your report is confusing or seems incomplete, a second opinion is a reasonable and common next step.
The World Health Organization classification of lymphoid tumours recognises more than 60 distinct subtypes of lymphoma, each with its own behaviour and treatment. This is why a lymphoma diagnosis is never made on the microscope appearance alone — it requires immunohistochemistry, flow cytometry and, for many subtypes, molecular testing to be confirmed. (Source: WHO Classification of Haematolymphoid Tumours, 5th edition, as referenced in NCCN and ESMO lymphoma guidelines.)
Most lymphoma pathology reports follow the same running order. Here is what each part is telling you.
| Section | What it describes | Why it matters |
|---|---|---|
| Specimen / clinical details | What tissue was sent — e.g. a whole lymph node, core, or bone marrow — and where from | A whole node (excisional biopsy) gives the most reliable diagnosis |
| Gross / macroscopic | Size and appearance of the sample to the naked eye | Confirms enough tissue was obtained for full testing |
| Microscopic description | How the cells and node architecture look under the microscope | Points toward the pattern of lymphoma (e.g. diffuse vs nodular) |
| Immunohistochemistry (IHC) | Surface markers such as CD20, CD30, CD3, BCL2 | Identifies the cell type and the exact subtype |
| Ki-67 / proliferation | Percentage of actively dividing cells | Suggests indolent (low) vs aggressive (high) behaviour |
| Molecular / genetic | Cell-of-origin, MYC and BCL2 rearrangements | Refines diagnosis and outlook for several subtypes |
| Final diagnosis | The named WHO subtype — the bottom line | This drives the entire treatment plan |
Report layouts vary between laboratories; not every report contains every section. The exact panel of tests depends on the suspected subtype, following NCCN and ESMO guidance.
A quick glossary for the words that come up again and again when reading a lymphoma report.
Proteins on the surface of your lymphoma cells, detected by IHC or flow cytometry. They act as a fingerprint of the cell type — for example, CD20 indicates a B-cell lymphoma and CD30 is seen in certain Hodgkin and aggressive lymphomas. Read our full guide to immunohistochemistry.
The percentage of tumour cells actively dividing. A low figure suggests an indolent, slow-growing lymphoma; a high figure suggests an aggressive one. It is read alongside the subtype, never on its own, because the same number means different things in different lymphomas.
In diffuse large B-cell lymphoma, molecular testing can classify the tumour by which normal B-cell it resembles. This "cell-of-origin" refines the expected behaviour and is recommended by NCCN and ESMO for this subtype.
Some aggressive B-cell lymphomas carry rearrangements in both the MYC and BCL2 genes — a pattern often called "double-hit". Detecting it changes how the disease is expected to behave, which is why genetic testing is part of a complete work-up for these subtypes.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received a lymphoma biopsy report and unsure what it means, or want to know if any tests are missing? CION's haematology team is here to walk you through it.
The final diagnosis line does not come from any single test. It is assembled from several layers of evidence, each cross-checking the others. Understanding this sequence explains why a report can take several days and why a small sample is often not enough.
Accurate diagnosis usually depends on preserving the architecture of a whole lymph node, which is why an excisional biopsy is preferred over a fine-needle aspirate. A whole node also provides enough tissue for the full panel of tests. When surgery is difficult, a core needle biopsy may be used instead. To understand the procedure itself, see what to expect from a lymph node biopsy. In some cases a bone marrow biopsy is added to check whether the marrow is involved.
Immunohistochemistry and flow cytometry identify the surface markers on the tumour cells. This "immunophenotype" is what separates a B-cell lymphoma from a T-cell one, and one subtype from another. It is also where treatment targets are found — for example, a strongly CD20-positive lymphoma may be suitable for an anti-CD20 monoclonal antibody, which your treating team would discuss on the treatment plan.
Molecular testing determines cell-of-origin and detects gene rearrangements such as MYC and BCL2. NCCN and ESMO recommend these for several subtypes because they change the expected behaviour of the disease. If your subtype usually warrants them but your report does not mention them, ask your team or seek a second opinion. Deciding which exact lymphoma subtype you have depends on all these layers together.
The pathology report is one input. To turn it into a treatment plan, CION's tumour board reads it alongside the rest of your work-up. This is where reading a lymphoma report connects to real decisions.
Your subtype is combined with your stage (how far the disease has spread), blood tests including LDH, and imaging. A PET-CT scan is often read using the Deauville score, and routine blood tests check your general health and organ function before treatment. If an enlarged node was found on a scan or your report mentions bulky disease, that too feeds into the plan.
Depending on subtype and stage, CION delivers chemotherapy, antibody-based immunotherapy, targeted therapy and precision radiation (IMRT) directly, along with active surveillance (watch-and-wait) monitoring for selected indolent lymphomas. Where a stem-cell transplant is needed, it is coordinated through accredited partner facilities. Specific regimens and drug names are discussed on the Lymphoma Treatment in Hyderabad page — this page focuses on understanding your report, not prescribing therapy.
Outlook depends on the whole picture, not the report alone. Published series show many lymphomas respond well — Hodgkin lymphoma commonly around 80–90% and diffuse large B-cell lymphoma around 60–70% long-term survival in reported cohorts (NCCN and ESMO). These are averages that vary considerably by individual, subtype, stage and response — they are not a prediction for any one person. Your treating team can explain what your specific report means for you.
Because lymphoma has so many subtypes and the diagnosis drives everything, a second opinion on the pathology is common and worthwhile — especially in these situations:
CION offers a dedicated, free written second-opinion service, including review of outside slides. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726. You can also explore our lymphoma doctors and lymphoma hospital in Hyderabad.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if the diagnosis was made on a small sample or key molecular tests have not yet been arranged.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.A lymphoma biopsy report describes what the pathologist saw when they examined your tissue. It typically records the specimen type (for example, a whole lymph node from an excisional biopsy), the microscopic appearance, the exact lymphoma subtype, and the results of special tests such as immunohistochemistry and flow cytometry. It often lists the markers found on the tumour cells (for example CD20 or CD30), a growth-fraction estimate, and any molecular findings. The final line — the diagnosis — names the subtype using the World Health Organization classification, which then guides your whole treatment plan.
CD markers are proteins on the surface of your lymphoma cells, detected by immunohistochemistry or flow cytometry. They act like a fingerprint that tells the pathologist which cell type the lymphoma came from. For example, CD20 points to a B-cell lymphoma, while CD30 is characteristic of certain Hodgkin and some aggressive lymphomas. These markers matter because they define the subtype and can identify targets for antibody-based therapy — for instance, an anti-CD20 monoclonal antibody. The specific combination of markers, read together, is what confirms the exact diagnosis rather than any single positive result on its own.
Ki-67 is a marker of how many tumour cells are actively dividing, reported as a percentage. A low Ki-67 suggests an indolent (slow-growing) lymphoma, while a high Ki-67 suggests an aggressive, fast-growing one. Some reports also describe the lymphoma as low-grade or high-grade based on the microscopic pattern. Grade is not the same as stage — grade describes how the cells behave, while stage describes how far the disease has spread. Both matter, but for different reasons. Your treating team reads Ki-67 alongside the subtype, not in isolation, because the same figure can mean different things in different lymphomas.
Modern lymphoma diagnosis increasingly relies on molecular and genetic testing of the biopsy tissue. This can determine the cell-of-origin in diffuse large B-cell lymphoma or detect rearrangements in genes such as MYC and BCL2 — the so-called "double-hit" pattern — which change the expected behaviour of the disease. NCCN and ESMO guidelines recommend these tests for several subtypes because they refine the diagnosis and inform the plan. If your report does not mention them and your subtype usually warrants them, that is a good reason to seek a second opinion before treatment begins.
Accurate lymphoma diagnosis usually needs the architecture of a whole lymph node preserved, which is why an excisional biopsy is preferred over a fine-needle aspirate. A needle sample can miss the pattern the pathologist needs to see and may not provide enough tissue for the full panel of immunohistochemistry, flow cytometry and molecular tests. Sometimes a core needle biopsy is used when surgery is not straightforward. If your diagnosis was made on a small sample and remains uncertain, a repeat biopsy of the whole node is often recommended. See what to expect from a lymph node biopsy.
It is common for a first report to be preliminary while immunohistochemistry, flow cytometry or molecular tests are still pending. Lymphoma has more than 60 recognised subtypes, and getting the exact one right is worth the extra days. A "descriptive" or "cannot classify" report does not mean anything is being hidden from you — it means the pathologist is being careful. In these situations an expert haematopathology review is valuable. CION arranges review of outside slides and pending tests, and offers a free written second opinion so your treatment starts from a confirmed diagnosis.
The report contributes to your prognosis but does not define it on its own. The subtype, grade and molecular findings from the report are combined with your stage, blood tests such as LDH, imaging including the Deauville score, and your general health to estimate the likely outlook. Published series show many lymphomas respond well — Hodgkin lymphoma commonly around 80–90% and diffuse large B-cell lymphoma around 60–70% long-term survival in reported cohorts (NCCN and ESMO). These figures vary considerably by individual and are averages, not predictions. Your treating team can explain what your specific report means for you.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.